PL3519398T3 - Związek pirydynowy - Google Patents

Związek pirydynowy

Info

Publication number
PL3519398T3
PL3519398T3 PL17780169T PL17780169T PL3519398T3 PL 3519398 T3 PL3519398 T3 PL 3519398T3 PL 17780169 T PL17780169 T PL 17780169T PL 17780169 T PL17780169 T PL 17780169T PL 3519398 T3 PL3519398 T3 PL 3519398T3
Authority
PL
Poland
Prior art keywords
pyridine compound
pyridine
compound
Prior art date
Application number
PL17780169T
Other languages
English (en)
Inventor
Hiroaki Inagaki
Yoshihiro Shibata
Hidenori Namiki
Hideaki KAGEJI
Kiyoshi Nakayama
Yasuyuki Kaneta
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of PL3519398T3 publication Critical patent/PL3519398T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
PL17780169T 2016-09-29 2017-09-28 Związek pirydynowy PL3519398T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016191725A JP2018052878A (ja) 2016-09-29 2016-09-29 ピリジン化合物
PCT/GB2017/052913 WO2018060714A1 (en) 2016-09-29 2017-09-28 Pyridine compound
EP17780169.3A EP3519398B1 (en) 2016-09-29 2017-09-28 Pyridine compound

Publications (1)

Publication Number Publication Date
PL3519398T3 true PL3519398T3 (pl) 2021-06-28

Family

ID=60020249

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17780169T PL3519398T3 (pl) 2016-09-29 2017-09-28 Związek pirydynowy

Country Status (32)

Country Link
US (2) US10851092B2 (pl)
EP (2) EP3519398B1 (pl)
JP (2) JP2018052878A (pl)
KR (1) KR102520543B1 (pl)
CN (2) CN113788824A (pl)
AU (2) AU2017335242C1 (pl)
BR (1) BR112019006047A2 (pl)
CA (1) CA3035860A1 (pl)
CL (1) CL2019000844A1 (pl)
CO (1) CO2019004034A2 (pl)
CY (1) CY1123988T1 (pl)
DK (1) DK3519398T3 (pl)
EA (1) EA037103B1 (pl)
EC (1) ECSP19030134A (pl)
ES (1) ES2868748T3 (pl)
HR (1) HRP20210447T1 (pl)
HU (1) HUE054824T2 (pl)
IL (1) IL265630B (pl)
LT (1) LT3519398T (pl)
MA (2) MA54910A (pl)
MD (1) MD3519398T2 (pl)
MX (1) MX2019003747A (pl)
PE (1) PE20190805A1 (pl)
PH (1) PH12019500480A1 (pl)
PL (1) PL3519398T3 (pl)
PT (1) PT3519398T (pl)
RS (1) RS61640B1 (pl)
SG (1) SG11201901937WA (pl)
SI (1) SI3519398T1 (pl)
UA (1) UA123964C2 (pl)
WO (1) WO2018060714A1 (pl)
ZA (1) ZA201902232B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787018B (zh) 2015-11-02 2022-12-11 美商纜圖藥品公司 轉染過程重排之抑制劑
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
LT3773589T (lt) 2018-04-03 2024-02-12 Blueprint Medicines Corporation Ret inhibitorius, skirtas naudoti vėžiui gydyti, esant ret pakitimui
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
EP4062938A4 (en) * 2019-11-18 2023-11-29 Chugai Seiyaku Kabushiki Kaisha COMBINATION MEDICINAL PRODUCTS
CN113121524B (zh) 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021164741A1 (zh) * 2020-02-20 2021-08-26 南京明德新药研发有限公司 苯基双酰胺类化合物
JP7461605B2 (ja) 2020-02-20 2024-04-04 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 キノリン系化合物
WO2022238706A1 (en) 2021-05-14 2022-11-17 Bp Asset Viii, Inc. Ret inhibitor for the treatment of ret altered medullary thyroid cancer or ret altered non-small cell lung cancer
WO2023239422A2 (en) 2021-10-22 2023-12-14 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
CN115090331B (zh) * 2022-07-21 2023-05-16 扬州大学 超分子手性催化剂、其制备方法及其催化d-a反应的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
AU2004270733B2 (en) 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
EP1994023A1 (en) 2006-03-02 2008-11-26 AstraZeneca AB Quinazoline derivatives
WO2007099323A2 (en) 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives
WO2007113565A1 (en) 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
WO2007113548A1 (en) 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
CN102333765B (zh) * 2009-02-27 2015-01-14 帝人制药株式会社 基于使用过渡金属催化剂的偶联法的苯基取代杂环衍生物的制造方法
JP2013502429A (ja) 2009-08-19 2013-01-24 アムビト ビオスシエンセス コルポラチオン ビアリール化合物及びその使用方法
EP2470173B1 (en) 2009-08-25 2016-04-27 Abraxis BioScience, LLC Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
CA2798209A1 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
EP2651930B1 (en) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
AU2013289938A1 (en) 2012-07-13 2015-01-29 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
CN105051027A (zh) 2013-03-15 2015-11-11 葛兰素史密斯克莱知识产权发展有限公司 作为转染期间重排(ret)激酶抑制剂的吡啶衍生物
SG11201601341QA (en) * 2013-08-30 2016-03-30 Ambit Biosciences Corp Biaryl acetamide compounds and methods of use thereof
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
EP3135667A4 (en) * 2014-04-24 2017-11-01 Mitsubishi Tanabe Pharma Corporation Novel 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof
EP3191450B1 (en) * 2014-09-10 2019-04-10 GlaxoSmithKline Intellectual Property Development Limited Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
MY187169A (en) * 2014-09-10 2021-09-07 Glaxosmithkline Ip Dev Ltd Novel compounds as rearranged during transfection (ret) inhibitors
US10626094B2 (en) 2014-10-14 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
CN104844589B (zh) 2014-12-26 2018-04-20 中国科学院合肥物质科学研究院 一种pi3k激酶抑制剂
US10202365B2 (en) * 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物

Also Published As

Publication number Publication date
ECSP19030134A (es) 2019-08-30
MA46337A (fr) 2019-08-07
EA037103B1 (ru) 2021-02-05
KR102520543B1 (ko) 2023-04-10
ES2868748T3 (es) 2021-10-21
JP2019534871A (ja) 2019-12-05
CA3035860A1 (en) 2018-04-05
WO2018060714A1 (en) 2018-04-05
IL265630B (en) 2021-10-31
AU2021261899A1 (en) 2021-12-02
US20210163464A1 (en) 2021-06-03
AU2017335242B2 (en) 2021-08-19
US10851092B2 (en) 2020-12-01
AU2017335242A1 (en) 2019-05-02
PH12019500480A1 (en) 2019-08-05
LT3519398T (lt) 2021-05-10
RS61640B1 (sr) 2021-04-29
EP3828178A1 (en) 2021-06-02
JP7098609B2 (ja) 2022-07-11
SI3519398T1 (sl) 2021-07-30
ZA201902232B (en) 2022-12-21
KR20190086442A (ko) 2019-07-22
PE20190805A1 (es) 2019-06-10
PT3519398T (pt) 2021-03-24
AU2017335242C1 (en) 2021-12-09
MA54910A (fr) 2022-04-13
HUE054824T2 (hu) 2021-10-28
MA46337B1 (fr) 2021-04-30
SG11201901937WA (en) 2019-04-29
MX2019003747A (es) 2019-09-19
JP2018052878A (ja) 2018-04-05
HRP20210447T1 (hr) 2021-07-23
CO2019004034A2 (es) 2019-07-10
IL265630A (en) 2019-05-30
CN110036007A (zh) 2019-07-19
UA123964C2 (uk) 2021-06-30
BR112019006047A2 (pt) 2019-06-25
US20200039974A1 (en) 2020-02-06
MD3519398T2 (ro) 2021-05-31
EP3519398B1 (en) 2021-02-24
EA201990833A1 (ru) 2019-10-31
EP3519398A1 (en) 2019-08-07
CL2019000844A1 (es) 2019-06-07
CN110036007B (zh) 2021-10-15
CY1123988T1 (el) 2022-05-27
CN113788824A (zh) 2021-12-14
DK3519398T3 (da) 2021-03-29

Similar Documents

Publication Publication Date Title
ZA201902232B (en) Pyridine compound
HK1256022A1 (zh) 唑類取代的吡啶化合物
HK1255832A1 (zh) 吡喃並二吡啶化合物
GB201521524D0 (en) Compound
ZA201707090B (en) Novel pyridinium compounds
EP3366674A4 (en) PYRIDINE COMPOUND
ZA201701783B (en) Pyridine compounds
GB201617103D0 (en) Compound
DK3330264T3 (en) Pyridin substitueret 2-aminopyridin proteinkinase-inhibitorkrystal
ZA201706038B (en) Bicyclic pyridine compound
IL249210A0 (en) A pyridine derivative
GB201612652D0 (en) Novel compound
LT3208085T (lt) Lango glaistas
GB201610497D0 (en) Compound
GB201518950D0 (en) Compound
HK1251574A1 (zh) 四氫噁庚英吡啶化合物
GB201619531D0 (en) Compound
GB201619526D0 (en) Compound
GB201613035D0 (en) Compound
GB201608591D0 (en) Compound
GB201520393D0 (en) Compound
GB201520391D0 (en) Compound
GB201509303D0 (en) Compound